This section provides detailed information on referring cases for genetic confirmation of SARS-CoV-2 re-infections and breakthrough infections

Re-infection of SARS-CoV-2 is a rare entity. There have been only a few reports of SARS-CoV-2 re-infection reported from across the world. It is widely believed that genetic variants in the SARS-CoV-2 genome are responsible for re-infection. No data is yet available on host factors responsible for re-infection, though some evidence points to the key role of germinal centre development and re-infection, suggesting a potential subtle primary or secondary immunodeficiency.

Starting the Referral

Let us know

Please fill in the online proforma to let us know about someone under your care or you know with COVID-19 re-infection. We would get back to you with the details and documentation and information on the logistics.


Referral requires the following (see section below)

  1. Patient Consents

  2. Samples

  3. Clinical Details

Sample Logistics

We would arrange for the sample transport and logistics of the samples from your office. We would get back to you with details on the same.The referral should not cost you anything.

Samples and Clinical Information


The consents for sampling and genetic studies need to be obtained in the standard format(s)


  1. RNA sample from NP swabs from previous and present COVID-19 infection.

  2. Blood sample (5ml)

Clinical Details

Clinical notes and investigation summaries from previous and present COVID-19 treatments. We follow the ISARIC CORE Case report format


This research is co-ordinated by researchers Dr Vinod Scaria and Dr Sridhar Sivasubbu at the CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB).

Please contact Dr Sridhar Sivasubbu OR Dr Vinod Scaria for any clarification / assistance

Office Memorandum from the Office of the Principal Scientific Advisor

SA/COVI D-1 9/2020 , Dated 21st, March, 2O2O

National research labs are permitted to access samples for COVlD-l9 related research from any government approved clinical testing site or access clinical samples received by them for testing, subject to ethical approval for such research. Results from such research are required to be expeditiously shared in open formats to maximise impact of research. Clinical care agencies are directed to enrich the open dataset by providing de-identified clinical data. Hospitals (Centre, State and private), to cooperate with national labs for clinical sample collection